In recent years, there have been more references (RCTs, case reports, and retrospectives studies) demonstrating that the skin lesions of TSC could be effectively treated with topical mTOR inhibitors, especially sirolimus, which is the oldest mTOR inhibitor, with a well-known safety profile [12,28]. The gene discussed is MTOR; the disease is tuberous sclerosis.